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Plasma microrna expression profile 
for reduced ejection fraction 
in dilated cardiomyopathy
Maria Calderon‑Dominguez1*, Thalía Belmonte1, Maribel Quezada‑Feijoo2,3, 
Mónica Ramos2,3, Juan Calderon‑Dominguez1, Oscar Campuzano4,5,6, Alipio Mangas1,7,8 & 
Rocio Toro1,8* 
The left ventricular (LV) ejection fraction (EF) is key to prognosis in dilated cardiomyopathy (DCM). 
Circulating microRNAs have emerged as reliable biomarkers for heart diseases, included DCM. 
Clinicians need improved tools for greater clarification of DCM EF categorization, to identify high‑
risk patients. Thus, we investigated whether microRNA profiles can categorize DCM patients based 
on their EF. 179‑differentially expressed circulating microRNAs were screened in two groups: (1) 
non‑idiopathic DCM; (2) idiopathic DCM. Then, 26 microRNAs were identified and validated in the 
plasma of ischemic‑DCM (n = 60), idiopathic‑DCM (n = 55) and healthy individuals (n = 44). We identified 
fourteen microRNAs associated with echocardiographic variables that differentiated idiopathic DCM 
according to the EF degree. A predictive model of a three‑microRNA (miR‑130b‑3p, miR‑150‑5p and 
miR‑210‑3p) combined with clinical variables (left bundle branch block, left ventricle end‑systolic 
dimension, lower systolic blood pressure and smoking habit) was obtained for idiopathic DCM with a 
severely reduced‑EF. The receiver operating characteristic curve analysis supported the discriminative 
potential of the diagnosis. Bioinformatics analysis revealed that miR‑150‑5p and miR‑210‑3p target 
genes might interact with each other with a high connectivity degree. In conclusion, our results 
revealed a three‑microRNA signature combined with clinical variables that highly discriminate 
idiopathic DCM categorization. This is a potential novel prognostic biomarker with high clinical value.
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Dilated cardiomyopathy (DCM) is a heterogeneous heart disease characterized by the presence of left ventricu-
lar (LV) dilatation and systolic dysfunction in the absence of abnormal loading conditions or coronary artery 
disease sufficient to cause global systolic  impairment1,2. This entity encompasses different phenotypes, clinical 
features and etiologies with a common final pathway. The prevalence of DCM is estimated at more than one 
in 250 individuals and it has increased by 27% in the last ten years. Hence, DCM is a health burden worldwide 
that imposes huge economic healthcare concerns due to high hospitalization, morbidity and mortality  rates3.
The latest guidelines have established that the systolic ejection fraction (EF) discerns between heart failure 
(HF)  categories4. Left ventricular ejection fraction (LVEF) has been strongly associated with adverse cardiac 
outcome in  DCM5–7. Severely depressed EF, below 35%, has been shown in randomized clinical trials as a sud-
den death risk  factor8. Nevertheless, the need for expert staff and inaccessible or excessive radiation imaging 
techniques impede clinical follow-up. Furthermore, highly time-consuming imaging techniques restrict access 
to the LV systolic function in the DCM population. Circulating levels of B-type natriuretic peptide or related 
molecules are very useful for clinical tailoring. However, they are not highly specific, as they are not good as 
systolic function  markers4. The lack of solid biomarkers and the limitations of imaging cardiovascular tests to 
categorize LVEF in DCM urge the investigation of a new, reliable tool.
MicroRNAs (miRNAs) are evolutionary conserved non-coding RNA molecules of 19–25 nucleotides that 
play crucial roles in modulating the expression of most proteins at post-transcriptional  level9. Their properties 
make them the most widely studied extracellular RNAs as diagnostic, prognostic and therapeutic markers in the 
cardiovascular  field10–12. Several studies have described the relationship between DCM and miRNA  profiles13–15. 
Therefore, a deeper knowledge of miRNA and the LVEF subcategories in the DCM population is needed to 
identify high-risk patients.
In the current study, we evaluated plasma miRNAs as potential biomarkers to discriminate severe from 
moderate reduced EF in a DCM population.
Results
Demographics and clinical manifestations in the patients. The subject characteristics are shown 
in Table 1. The mean age for control, idiopathic, and ischemic DCM patients was 39.1 ± 12.8, 67.3 ± 9.2, and 
68.2 ± 8.4 years old. Most of the patients enrolled were men. As expected, LVEF and LVESD differed signifi-
cantly between DCM patients and control subjects (p < 0.0001, for both comparisons). DCM group exhibited 
an increase in left atrium diameter (LA) and volume, sphericity index, and E/e’ ratio, compared with the control 
group. Regarding  DCMMOD group, ischemic patients showed significantly reduced heart rate, LVEF and right 
ventricle diameter compared with idiopathic patients (p = 0.014, p = 0.020 and p = 0.024, respectively). As to the 
 DCMSEV group, 10 ischemic patients had diabetes mellitus type 2, while only 4 idiopathic patients showed this 
comorbidity (p = 0.01). In both cases, sphericity index was significantly reduced in ischemic patients (p = 0.047 
for  DCMMOD group and p = 0.03 for  DCMSEV group).
Screening study. The study design is shown in Fig. 1. We first screened 179-differentially expressed cir-
culating miRNAs in 30 idiopathic and non-idiopathic DCM age- and sex-matched patients (see Table S1 and 
Fig. S1 in Supplementary Material). In total, 26 miRNAs were significantly expressed according to the selection 
criteria at high levels and statistical significance (median Cq < 32 and detected in at least 80% of all samples and 
p < 0.05). The candidates selected for further analysis were let-7 g-5p, let-7a-5p, miR-1-3p, miR-16-5p, miR-16–
2-3p, miR-19b-3p, miR-25-3p, miR-29a-3p, miR-30b-5p, miR-30e-3p, miR-130b-3p, miR-133a-3p, miR-133b, 
miR-142-3p, miR-145-5p, miR-150-5p, miR-192-5p, miR-199a-3p, miR-210-3p, miR-215-5p, miR-324-3p, miR-
363-3p, miR-454-3p, miR-532-5p, miR-629-5p and miR-660-5p (Table 2).
Validation study and association with a population that has a reduced ejection fraction and 
DCM. The ischemic and idiopathic DCM populations are presented as  DCMMOD and  DCMSEV groups based 
on their LVEF, ≤ 30% and > 31–49%, respectively. We investigated the potential value of the miRNA candidates 
to discriminate between the  DCMSEV vs. the  DCMMOD population and their association with echocardiographic 
parameters (Table 3 and Table S2). Only the idiopathic  DCMSEV group showed an association between LVEF 
and fourteen miRNA candidates (Table 4). These miRNAs were let-7a-5p, let 7 g-5p, miR-19b-3p, miR-25-3p, 
miR-29a-3p, miR-30b-5p, miR-30e-3p, miR-142-3p, miR-145-5p, miR-150-5p, miR-199a-3p, miR-210-3p, , 
miR-324-3p and miR-660-5p. No association was found in the idiopathic  DCMMOD cohort with LVEF (Table 4). 
Moreover, the correlation between other echocardiographic variables and individual miRNAs was also identi-
fied. All these miRNAs significantly correlated with LVEF in  DCMSEV patients. In addition, these miRNAs in 
the  DCMMOD group were significantly correlated with LV end-systolic dimension (LVESD) and the left atrium 
dimension (LA).
A graphical illustration of the potential miRNA expression levels to discriminate between  DCMSEV and 
 DCMMOD in the idiopathic group is represented in Figs. 2 and 3. In all cases, the average miRNA levels were 
significantly higher in the idiopathic DCM group than in healthy subjects. Moreover, we found a significant 
increase in these circulating miRNA levels in plasma from  DCMSEV compared with  DCMMOD idiopathic patients.
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Combining miRNAs for DCM detection and subtype categorization. The ability of these miRNAs 
to discriminate between DCM with moderate and severe EF impairment was assessed using AUC-ROC. All 
individual miRNAs show an AUC ≥ 0.7, except for miR-30b-5p, miR-210-3p and miR-324-3p that were 0.69, 
0.68 and 0.69, respectively. The highest AUC values achieved by single miRNAs was obtained for miR-145-5p 
with an AUC of 0.78 (95% CI: 0.65–0.91; p = 0.0029). The AUC values obtained for let-7a-5p, let 7 g-5p, miR-
19b-3p, miR-25-3p, miR-29a-3p, miR-30e-3p, miR-142-3p, miR-150-5p, miR-199a-3p, and miR-660-5p when 
 DCMSEV were compared to  DCMMOD in the idiopathic group, as well as sensitivity for a whole range of specifici-
ties, are shown in Table 5.
A predictive model to determinate the association of microRNAs with a very reduced ejection 
fraction in idiopathic DCM. Statistical modelling was used to determine the association of the fourteen 
miRNA candidates with the patient characteristics. A multivariate model was built up with three predictive 
circulating miRNAs, miR-130b-3p, miR-150-5p and miR-210-3p. The multivariate logistic regression analy-
ses revealed that circulating miR-130b-3p, miR-150-5p and miR-210-3p levels were associated with left bun-
dle branch block (LBBB), LVESD, lower systolic blood pressure (SBP) and smoking habit in our idiopathic 
 DCMSEV group. Based on this analysis, LBBB (OR: 18.13; 95% CI: 1.28- 257.21; p = 0.014), LVESD (OR: 1.24; 
95% CI: 1.01–1.53; p = 0.01), SBP (OR: 0.97; 95% CI: 0.91–1.03; p = 0.329), smoking habit (OR: 01; 95% CI: 
1.44–630.02; p = 0.007), plasma miR-130b-3p (OR: 0; 95% CI: 0.1–1.57; p = 0.01), miR-150-5p (OR: 36.06; 95% 
Table 1.  Baseline characteristics of of the study groups. Data presented as mean ± SD for continuous variables 
and as percentage for categorical variables. NS, no significant. Abbreviations: ACE I, angiotensin-converting 
enzyme; ARA II, angiotensin II receptor antagonist; b.p.m, beats per minute; DBP, diastolic blood pressure; 
 DCMMOD, dilated cardiomyopathy with ejection fraction ≥ 31–49%;  DCMSEV, dilated cardiomyopathy with 
ejection fraction ≤ 30%; E/e’, ratio of mitral early diastolic flow velocity over tissue Doppler lateral mitral 
annular lengthening velocity; LBBB, left bundle branch block; LVEDD, left ventricle end-diastolic diameter; 
LVEF, left ventricle ejection fraction; LVESD, left ventricle end-systolic diameter; MAPSE, mitral annular plane 





p Healthy controlEtiology Idiopathic Ischemic Idiopathic Ischemic
n 40 46 15 14 44
Demographics
Age (years) 67.6 ± 9.4 68.0 ± 8.3 NS 66.5 ± 8.4 68.7 ± 8.4 NS 39.1 ± 12.8
Sex (male, %) 70.0 76.1 NS 60.0 92.9 0.045 52.3
SBP (mm Hg) 124.1 ± 21.0 125.0 ± 14.5 NS 113.8 ± 17.5 118.7 ± 11.3 NS 114.4 ± 8.6
DBP (mm Hg) 71.7 ± 6.8 72.2 ± 11.1 NS 73.1 ± 10.6 70.8 ± 9.8 NS 74.4 ± 8.1
Heart rate (b.p.m) 71.0 ± 13.3 65.1 ± 12.9 0.014 67.1 ± 5.4 68.0 ± 11.5 NS 63.7 ± 11.4
LBBB (%) 15 8.7 NS 33.3 14.3 NS 0
Body mass index (kg/m2) 29.4 ± 5.6 29.1 ± 4.4 NS 28.0 ± 5.3 27.5 ± 3.7 NS 24.0 ± 3.5
Diabetes Mellitus (%) 40 46.7 NS 26.7 71.4 0.019 0
Smoking habit (%) 40 47.8 NS 73 69.2 NS 0
II-III NYHA functional class (%) 12.5 10.9 NS 20 35.7 NS 0
Medications
ACE I (%) 42.5 41.3 NS 60 35.7 NS 0
Antiplatelet (%) 37.5 30.4 NS 26.7 42.9 NS 0
ARA II (%) 33.3 41.3 NS 55 71.4 0.047 0
Beta-blocker (%) 65 71.7 NS 100 100 NS 0
Statin (%) 22.5 32.6 NS 33.3 28.6 NS 29.5
Echocardiography
LVEF (%) 39.0 ± 4.5 36.7 ± 4.0 0.020 24.1 ± 4.4 25.7 ± 3.6 NS 66.2 ± 5.2
LVEDD (mm) 63.1 ± 4.1 63.3 ± 6.2 NS 60.5 ± 5.4 60.4 ± 5.8 NS 46.2 ± 4.9
LVESD (mm) 45.8 ± 14.0 46.1 ± 13.5 NS 54.6 ± 5.4 42.9 ± 18.6 NS 28.4 ± 5.8
Right ventricle (mm) 37 ± 8.5 33.4 ± 7.3 0.024 37.9 ± 11.7 34.9 ± 7.2 NS 27.2 ± 4.0
MAPSE 11 ± 2.3 10.9 ± 2.1 NS 1 ± 3.2 9.5 ± 2.0 NS 18.9 ± 2.2
TAPSE 20 ± 4.7 19.8 ± 4.7 NS 19. 2 ± 6.3 19.5 ± 3.6 NS 21.4 ± 3.3
Aortic root (mm) 33.9 ± 5.0 33.2 ± 4.8 NS 30. 3 ± 6.2 32.2 ± 3.5 NS –
E/e’ ratio 15.2 ± 6.8 15.1 ± 6.5 NS 15.2 ± 8.1 16.9 ± 8.7 NS 7.5 ± 1.7
Left Atrium (mm) 46.7 ± 9.2 44.3 ± 7.7 NS 41.1 ± 8.2 45.1 ± 7.3 NS 35.8 ± 8.3
Sphericity index 0.8 ± 0.3 0.7 ± 0.1 0.047 0.9 ± 0.27 0.7 ± 0.1 0.032 0.5 ± 0.1
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CI: 1.64–794.78; p = 0.006) and miR-210-3p (OR: 687.53; 95% CI: 0.9–527,268.21; p < 0.001) were independent 
influencing factors for idiopathic  DCMSEV (Table 6). In addition, the Akaike Information Criterion (AIC) of our 
model showed a value of 35.406. The AIC for a model just with a combination of miR-150-5p and miR-210-3p 
levels showed a higher value (AIC: 61.393). This lower value indicates that our model has a better fit.
The potential usefulness of our model for identifying the idiopathic  DCMSEV population was obtained with 
a ROC curve analysis. As shown in Fig. 4, the AUC was 0.96 (95% CI: 0.884–1.00; p < 0.001).
miRNA‑gene network analysis. The hypothetical functions of three miRNAs were assessed with the 
miRDB database to reach the target mRNAs. The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways database identified the biological and molecular processes. The miR-130b-3p, miR-
150-5p and miR-210-3p were associated with 917, 902 and 83 mRNAs in the miRDB database, respectively 
(Fig. 5A). The analysis revealed that most of these genes are involved in signalling and regulation of the cellu-
lar and metabolic process and genetic information processing (Figs. 5B–C). For instance, the genes are deeply 
involved in the transcription pathway since these miRNAs regulate the expression of the RNA Polymerase II, 
transcription factors or alternative splicing. In addition, other target genes are implicated in the nitrogen com-
pound metabolic process or in response to oxygen levels, among others (extended in Fig. S3).
On the other hand, the protein–protein interaction networks (PPI) analysis networks related to miR-210-3p 
were analysed using the search tool for the retrieval of interacting genes (STRING) (Fig. 5D). Our in-silico 
model showed that ISCU and other mitochondrial activity-related proteins, as well as SDHD and NDUFA4, are 
targets of miR-210-3p. Moreover, the analysis revealed that genes targeted by miR-150 and miR-210 showed a 
significant PPI enrichment (p = 0.00459) (Figure S4 and Table S3). These results demonstrated that target genes 
of miR-210-3p and miR-150-5p may interact with each other.
Discussion
We analysed the circulating miRNA signature of the ischemic and idiopathic DCM population stratified in 
severely and moderately reduced EF, ≤ 30% and 31–49% respectively. Our study reports, for the first time, a 
signature of three circulating miRNAs (miR-130b-3p, miR-150-5p and miR-210-3p) that allow us to discrimi-
nate between idiopathic  DCMMOD and  DCMSEV subjects. Furthermore, this circulating miRNA panel in plasma 
defines idiopathic  DCMSEV from ischemic etiology.
LVEF is the cornerstone of DCM outcome. Optimal pharmacological and non-pharmacological decisions, 
mostly based on LVEF, have improved DCM prognosis  drastically16. Major arrhythmogenic episodes, sudden 
death events and mortality are related to DCM with lower EF ≤ 35%7. The impact of stratifying the severity of sys-
tolic impairment is crucial in DCM as  shown6,7,17, but access to the EF has several limitations. The need for expert 
professionals, intra- and inter-observational differences or time-consuming imaging techniques in transthoracic 
Figure 1.  Flowchart of the study design strategy. This figure illustrates the experimental workflow of the study 
including screening, validation and EF status of DCM patients. Abbreviations: DCM, dilated cardiomyopathy; 
 DCMMOD, dilated cardiomyopathy with ejection fraction ≥ 31–49%;  DCMSEV, dilated cardiomyopathy with 
ejection fraction ≤ 30%; EF, ejection fraction.
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echocardiography or cardiac magnetic resonance, as well as inaccessible or excessive radiation imaging tech-
niques, make it difficult to monitor the patient. The lack of a specific circulating biomarker to stratify LVEF and 
the limitations of cardiac imaging tests lead to the need to investigate a novel tool for this at-risk population.
Some studies have struggled to relate preserved and impaired LVEF to HF  categorization18–20. The dysregula-
tion of miRNAs related to DCM diagnosis and its etiology has scarcely been characterized nor categorization 
of the EF has not been reported in this  population14,15,21. Some groups have worked on the reverse remodeling 
of LV in DCM or the signalling  network22. To the best of our knowledge, no study has focused on LVEF in the 
DCM population and circulating miRNA.
In the present study, fourteen plasma miRNAs showed discriminative power to define  DCMSEV vs.  DCMMOD 
idiopathic patients based on their correlation to some echocardiographic variables. The idiopathic  DCMSEV 
group showed an association between LVEF with these miRNAs. In the case of  DCMMOD patients, the miRNAs 
were associated with LVESD, and LA. Remarkably, it has been suggested that pressure overload in earlier stages 
of DCM and elevated LV filling pressures lead to a hemodynamic imbalance that justifies the increased LA and 
LVESD in this  cohort23,24.. Interestingly, some of these fourteen miRNAs have been related to HF and DCM 
patients with an EF < 30%, compared with healthy controls. Circulating levels of let-7a-5p were significantly 
upregulated in HF  patients25. Myocardial and circulating miR-30 levels were significantly increased in DCM 
 patients22. We present a novel, reliable fingerprint of circulating miRNAs to discriminate between idiopathic 
 DCMMOD and  DCMSEV subjects.
A multiparametric model was performed as a potential tool for the diagnosis of idiopathic  DCMSEV. A panel 
comprised of a combination of three circulating miRNAs (miR-130b-3p, miR-150-5p and miR-210-3p) with 
four clinical variables (LBBB, LVESD, SBP and smoking habit) showed a high-yield diagnostic accuracy with an 
AUC of 0.96. Significantly, miR-150-5p and miR-210-3p had a positive value while miR-130b-3p had a negative 
value for a diagnosis of idiopathic DCM.SEV.
A total of 1902 genes were predicted to be targeted by these three miRNAs. Although they have been described 
as key hypoxia-related miRNA, our in-silico analysis revealed that they are more than silent players in hypoxia. 
Hence, these miRNAs may influence  DCMSEV devolvement, promoting heart injury. MiR-210-3p and miR-150-5p 
share targeted genes linked within the cellular proliferation, differentiation oxidative stress and  apoptosis26–29. 
The miR-210 expression has been extensively studied in several cardiovascular-related diseases with contro-
versial  results30–33. Its overexpression reduces mitochondrial reactive oxygen species production, and promotes 
cardiomyocyte proliferation, cell survival and angiogenesis post-myocardial  infarction30,31. In disagreement, 
Table 2.  Peripheral microRNA levels in the Idiopathic and Ischemic DCM vs. healthy control. Data presented 
as median (Q1-Q3). Samples size is indicated. Abbreviations: DCM. dilated cardiomyopathy.
microRNA
Healthy control Idiopathic DCM Ischemic DCM
n median (Q1-Q3) n median (Q1-Q3) p value n median (Q1-Q3) p value
let-7a-5p 44 6.543 (6.308–6.832) 55 6.511 (6.308–7.207) 0.6636 60 7.155 (6.507–7.626) 0.0001
let-7 g-5p 44 6.268 (6.095–6.477) 55 6.303 (6.095–6.939) 0.3767 60 6.555 (6.147–7.034) 0.0236
miR-1-3p 44 4.101 (3.878–4.460) 55 4.238 (3.878–5.059) 0.0611 60 4.491 (3.552–5.038) 0.1142
miR-16-5p 44 7.634 (7.379–7.900) 55 7.658 (7.379–8.304) 0.0046 60 8.025 (7.714–8.300) 0.0017
miR-16–2-3p 44 4.967 (4.706–5.281) 55 7.035 (6.773–5.609) 0.0043 60 5.363 (5.003–5.573) 0.0026
miR-19b-3p 44 7.014 (6.773–7.230) 55 6.542 (6.199–7.637) 0.008 60 7.517 (7.103–7.751) 0.0006
miR-25-3p 44 6.487 (6.199–6.751) 55 6.230 (6.052–7.178) 0.0011 60 6.917 (6.620–7.127) 0.0017
miR-29a-3p 44 5.480 (5.297–5.643) 55 4.951 (4.730–6.233) 0.0001 60 5.951 (5.630–6.304) 0.0001
miR-30b-5p 44 6.197 (6.052–6.431) 55 4.913 (4.745–6.739) 0.9142 60 6.525 (6.032–6.992) 0.0229
miR-30e-3p 44 4.923 (4.745–5.165) 55 5.072 (4.858–5.559) 0.145 60 5.346 (4.793–5.722) 0.0127
miR-130b-3p 44 5.058 (4.858–5.275) 55 4.483 (4.167–5.849) 0.0001 60 5.610 (5.056–5.904) 0.0002
miR-133a-3p 44 4.451 (4.167–4.741) 55 4.164 (3.843–5.412) 0.0001 60 4.873 (4.273–5.439) 0.0042
miR-133b 44 4.129 (3.843–4.437) 55 6.950 (6.690–5.028) 0.0019 60 4.491 (3.909–5.105) 0.0026
miR-142-3p 44 6.932 (6.690–7.217) 55 5.454 (5.279–7.588) 0.9753 60 7.425 (7.007–8.022) 0.0001
miR-145-5p 44 5.423 (5.279–5.629) 55 5.504 (5.313–6.044) 0.2254 60 5.867 (5.473–6.385) 0.0001
miR-150-5p 44 5.520 (5.313–5.696) 55 4.970 (4.665–6.133) 0.1293 60 5.803 (5.377–6.053) 0.0634
miR-192-5p 44 4.928 (4.665–5.152) 55 6.231 (6.110–5.607) 0.0708 60 5.293 (4.893–5.486) 0.0075
miR-199a-3p 44 6.218 (6.110–6.390) 55 4.512 (4.314–6.967) 0.0007 60 6.628 (6.018–7.044) 0.0047
miR-210-3p 44 4.514 (4.314–4.705) 55 4.809 (4.544–5.317) 0.0001 60 5.039 (4.683–5.478) 0.0001
miR-215-3p 44 4.770 (4.544–4.997) 55 5.536 (5.299–5.397) 0.0479 60 5.101 (4.720–5.397) 0.0098
miR-324-3p 44 4.892 (4.728–5.139) 55 5.318 (4.969–5.554) 0.0079 60 5.397 (4.957–5.689) 0.0002
miR-363-3p 44 5.260 (4.969–5.555) 55 3.845 (3.281–5.946) 0.002 60 5.750 (5.389–5.893) 0.0006
miR-454-3p 44 3.759 (3.281–4.098) 55 4.704 (4.454–4.437) 0.7829 60 4.130 (3.298–4.699) 0.0061
miR-532-5p 44 4.668 (4.454–4.854) 55 5.535 (5.297–5.344) 0.083 60 5.207 (4.782–5.398) 0.0002
miR-629-5p 44 4.332 (4.104–4.680) 55 5.281 (4.854–5.72)  < 0.0001 60 5.182 (4.769–5.813)  < 0.0001
miR-660-5p 44 4.936 (4.730–5.162) 55 5.436 (5.104–5.639) 0.0001 60 5.454 (5.092–5.614) 0.0001
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Sun et al. confirmed that miR-210 induced oxidative stress and repressed mitochondrial  function34. Our in-silico 
model showed that several mitochondrial activity-related proteins, are targets of miR-210-3p. Downregulation of 
these proteins may influence mitochondrial activity. Hence, our data are in agreement with previous studies that 
demonstrate impaired mitochondrial function in idiopathic  DCM35,36. On the other hand, miR‐150 levels have 
been described as a responsive protector in ischemic heart  disease37–39 and  DCM40. MiR-150 protects the heart 
from ischemic injury by inhibiting the inflammatory response and repressing pro-apoptotic gene  expression39. 
Otherwise, a different role has been defined for miR-150. Its levels were upregulated in the infarct area compared 
with other cardiac zones, altering the LV  remodeling37. Furthermore, the downregulation of miR-150 targeted 
genes intensifies cardiac injury by deregulation of cell cycle-dependent intracellular  Ca2+ concentration, and 
oxidative stress  increase29; accompanied by an increase in reactive nitrogen disease, DNA damage and cardio-
myocyte  death41. MiR-130b-3p is negatively associated in our model. Instead of having a cytoprotective role, 
miR-130b-3p promotes cardiomyocytes  injury42. Although these three miRNAs have been studied in several 
cardiovascular-related diseases, their role is still unknown regarding idiopathic DCM.
Using predictive tools, we report an additive value to our model, including some clinical variables such 
as LBBB, LVESD, SBP and smoking habit. LBBB, SBP and LVESD are a risk factor marker of  HF5,43. Interest-
ingly, LBBB and lower EF have widely shown a better response to non-pharmacological treatment, such as an 
implantable  defibrillator44–46. Both clinical markers are related to neurohormonal activation in HF leading to 
severe myocardial  damage43. Our circulating levels of miRNAs may reflect a dysregulation of the cardiomyocyte 
protecting processes arising from severe impairment of the LVEF in the  DCMSEV population.
We have described a circulating miRNA signature as a useful and non-invasive tool for LVEF classification 
in idiopathic DCM patients. In addition, we have defined a parametric model, a miRNA panel and four clinical 
parameters that categorize DCM based on LV systolic impairment with the highest diagnostic values reported to 
date. The bioinformatics analysis may elucidate the underlying molecular and cellular mechanisms of idiopathic 
DCM. Our results present a step-forward personalized therapeutic strategy and management of this entity.
Table 3.  Peripheral microRNA levels for LVEF categorization in idiopathic and ischemic DCM. Data 
presented as median (Q1-Q3). Samples size is indicated. Abbreviations: DCM. dilated cardiomyopathy; 
 DCMMOD, dilated cardiomyopathy with ejection fraction ≥ 31–49%;  DCMSEV, dilated cardiomyopathy with 
ejection fraction ≤ 30%.
microRNA




p valuemedian (Q1-Q3) median (Q1-Q3) median (Q1-Q3) median (Q1-Q3)
let-7a-5p 6.460 (5.732–7.080) 6.909 (6.059–7.226) 0.009 7.206 (6.547–7.594) 7.125 (6.342–7.707) 0.893
let-7 g-5p 6.272 (5.894–6.482) 6.668 (6.000–7.010) 0.003 6.712 (5.940–6.993) 6.548 (6.138–7.054) 0.997
miR-1-3p 4.772 (4.493–5.241) 4.398 (2.779–4.950) 0.003 4.732 (2.779–5.128) 4.432 (3.242–4.989) 0.995
miR-16-5p 8.127 (7.898–8.513) 7.900 (7.619–8.221) 0.552 7.930 (7.425–8.251) 8.040 (7.681–8.301) 0.997
miR-16–2-3p 5.386 (5.132–5.694) 5.233 (5.016–5.559) 0.651 5.338 (4.857–5.550) 5.381 (4.994–5.588) 0.999
miR-19b-3p 7.218 (6.949–7.581) 7.449 (7.112–7.637) 0.044 7.486 (6.814–7.671) 7.539 (7.100–7.775) 0.997
miR-25-3p 6.697 (6.293–7.524) 6.938 (6.638–7.175) 0.007 6.858 (6.320–7.047) 6.919 (6.577–7.153) 0.996
miR-29a-3p 5.746 (5.576–6.095) 5.973 (5.718–6.258) 0.0326 6.077 (5.176–6.289) 5.949 (5.635–6.329) 0.825
miR-30b-5p 5.880 (5.498–6.397) 6.488 (5.634–6.862) 0.011 6.684 (5.846–6.923) 6.468 (5.982–7.027) 0.946
miR-30e-3p 4.926 (4.563–5.320) 5.371 (4.697–5.622) 0.001 5.507 (4.551–5.699) 5.186 (4.779–5.781) 0.952
miR-130b-3p 5.653 (5.371–5.923) 5.493 (5.236–5.846) 0.956 5.625 (4.955–5.872) 5.542 (5.048–5.920) 0.834
miR-133a-3p 5.197 (4.906–5.412) 4.895 (4.429–5.433) 0.365 4.890 (3.212–5.439) 4.851 (4.269–5.429) 0.968
miR-133b 4.784 (4.459–5.196) 4.434 (3.899–4.994) 0.193 4.689 (3.204–5.061) 4.485 (3.890–5.111) 0.760
miR-142-3p 6.770 (5.961–7.348) 7.233 (6.286–7.600) 0.0005 7.749 (6.859–8.046) 7.384 (6.741–8.023) 0.340
miR-145-5p 5.389 (5.113–5.758) 5.654 (5.089–6.126) 0.005 6.005 (5.466–6.175) 5.761 (5.221–6.408) 0.998
miR-150-5p 5.539 (5.143–6.016) 5.790 (5.418–6.156) 0.004 5.446 (5.031–5.806) 5.852 (5.451–6.066) 0.916
miR-192-5p 5.192 (5.107–5.614) 5.119 (4.857–5.579) 0.438 5.179 (4.712–5.523) 5.294 (4.827–5.508) 0.757
miR-199a-3p 6.527 (6.240–6.733) 6.715 (6.367–7.000) 0.036 6.906 (5.961–7.026) 6.544 (6.104–7.081) 0.962
miR-210-3p 4.781 (4.340–5.179) 5.058 (4.655–5.364) 0.003 5.023 (4.382–5.479) 5.040 (4.679–5.479) 0.797
miR-215-3p 5.158 (4.784–5.616) 4.993 (4.662–5.389) 0.773 5.084 (4.449–5.356) 5.110 (4.670–5.401) 0.874
miR-296a-3p 6.099 (5.849–6.409) 5.883 (5.590–6.168) 0.032 6.077 (5.176–6.289) 5.949 (5.635–6.329) 0.825
miR-324-3p 5.040 (4.827–5.385) 5.360 (4.960–5.570) 0.001 5.454 (4.695–5.689) 5.371 (4.945–5.697) 0.858
miR-363-3p 5.698 (5.512–6.065) 5.576 (5.255–5.928) 0.778 5.757 (5.094–5.908) 5.712 (5.349–5.896) 0.999
miR-454-3p 3.069 (3.069–4.437) 3.069 (3.069–4.438) 0.926 4.442 (3.654–4.635) 4.051 (3.069–4.758) 0.418
miR-532-5p 5.152 (4.748–5.622) 4.917 (4.459–5.315) 0.285 5.207 (4.468–5.407) 5.192 (4.741–5.403) 0.985
miR-629-5p 4.902 (4.651–5.566) 5.538 (5.112–5.903) 0.123 5.465 (5.306–5.918) 5.852 (5.451–5.065) 0.979
miR-660-5p 5.184 (5.049–5.899) 5.465 (5.196–5.570) 0.034 5.454 (4.608–5.697) 5.4504 (5.050–5.624) 0.992
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There are several limitations to the current study. The study sample was small, but the patients who were 
included were strictly DCM subjects. Recently, it has been reported that sex differences might play a role in the 
prognosis of  DCM47,48. In our case, larger sample size is needed to validate these data. Therefore, before these 
novel biomarkers can be routinely used in clinical practice, the data should be replicated and extended to larger 
populations. Secondly, data on natriuretic peptides, troponin, or reverse remodeling were not available in all 
patients to compare to our results. Our sample was of patients in a chronic situation, who were not hospitalized 
but were prospectively followed in the outpatient clinic. Future studies should include these data. The dysregula-
tion of miRNAs related to DCM diagnosis and its etiology has scarcely been characterized and characterization 
of the EF has not been reported in this population. In the bioinformatic analysis, we only identified the genes 
targeted by miR-210-3p and miR-150-5p, since both are positively related to our logistic regression model. MiR-
130b-3p was not included in the PPI analysis since it is negatively related to our logistic model. In addition, 
the analysis of 1902 genes did not show clear results due to a large number of interactions and data overload. 
Finally, we have no evidence that these circulating miRNAs are directly secreted into the extracellular space 
from the heart. Thus, dedicated experiments on human heart samples are necessary to verify these results and 
bioinformatic predictions.
Conclusion
In conclusion, we identified a miRNAs fingerprint that is differentially expressed in the idiopathic  DCMSEV 
population. This signature arises as a potential clinical biomarker to discriminate DCM etiology and stratify its 
risk, based on the LVEF. The clinical usefulness of this miRNA panel as a diagnostic tool could lead to tailored 
treatment improving the DCM population outcome. In addition, the bioinformatics analysis results may be 
useful in elucidating the underlying mechanisms of idiopathic DCM.
Table 4.  Correlation between the echocardiographic parameter and individual microRNAs for LVEF 
categorization in idiopathic DCM. Abbreviations:  DCMMOD, dilated cardiomyopathy with ejection 
fraction ≥ 31–49%;  DCMSEV, dilated cardiomyopathy with ejection fraction ≤ 30%; LVEF, left ventricle ejection 
fraction; LVESD, left ventricle end-systolic diameter. Coefficient significant at p < 0.05.
microRNA
LVEF (%) LVESD (mm) Left atrial dimension (mm)
DCMSEV DCMMOD DCMSEV DCMMOD DCMSEV DCMMOD
Pearson r p Pearson r p Pearson r p Pearson r p Pearson r p Pearson r p
Let-7a-5p − 0.677 0.006 0.140 0.388 − 0.103 0.726 − 0.489 0.002 0.277 0.318 − 0.362 0.022
Let-7 g-5p − 0.609 0.016 0.181 0.269 − 0.286 0.321 − 0.408 0.011 0.368 0.269 − 0.532  < 0.001
miR-1-3p − 0.190 0.498 0.204 0.206 0.046 0.875 − 0.218 0.183 0.242 0.385 − 0.433 0.005
miR-16-5p − 0.190 0.498 0.204 0.206 0.046 0.875 − 0.218 0.183 0.242 0.385 − 0.433 0.005
miR-16–2-3p − 0.438 0.102 0.130 0.424 0.044 0.882 − 0.559  < 0.001 0.219 0.432 − 0.262 0.102
miR-19b-3p − 0.527 0.043 0.193 0.233 0.111 0.705 − 0.444 0.005 0.276 0.319 − 0.306 0.054
miR-25-3p − 0.538 0.039 0.106 0.515 0.077 0.795 − 0.544  < 0.001 0.155 0.580 − 0.246 0.127
miR-29a-3p − 0.641 0.010 0.168 0.300 0.180 0.538 − 0.261 0.109 0.337 0.219 − 0.336 0.034
miR-30b-5p − 0.603 0.017 0.179 0.269 − 0.312 0.278 − 0.376 0.018 0.313 0.256 − 0.436 0.005
miR-30e-3p − 0.629 0.012 0.234 0.145 − 0.130 0.658 − 0.335 0.037 0.385 0.157 − 0.347 0.028
miR-130b-3p − 0.394 0.146 0.094 0.564 0.109 0.710 − 0.296 0.067 0.554 0.032 − 0.269 0.093
miR-133a-3p − 0.455 0.088 0.092 0.574 0.160 0.584 − 0.359 0.025 0.208 0.456 − 0.348 0.028
miR-133b − 0.361 0.186 0.179 0.268 0.028 0.924 − 0.194 0.236 0.140 0.619 − 0.444 0.004
miR-142-3p − 0.569 0.027 0.210 0.193 − 0.080 0.787 − 0.417 0.008 0.359 0.189 − 0.349 0.027
miR-145-5p − 0.614 0.015 0.130 0.423 0.109 0.711 − 0.425 0.007 0.324 0.239 − 0.382 0.015
miR-150-5p − 0.540 0.038 0.178 0.272 − 0.148 0.614 − 0.357 0.025 0.327 0.234 − 0.419 0.007
miR-192-5p − 0.464 0.082 0.237 0.141 0.152 0.603 − 0.536  < 0.001 0.191 0.495 − 0.252 0.117
miR-199a-3p − 0.692 0.004 0.184 0.257 0.065 0.826 − 0.198 0.228 0.396 0.144 − 0.401 0.010
miR-210-3p − 0.555 0.032 0.188 0.244 0.056 0.848 − 0.405 0.011 0.285 0.304 − 0.287 0.073
miR-215-3p − 0.425 0.114 0.201 0.213 − 0.003 0.993 − 0.583 0.000 0.109 0.699 − 0.301 0.059
miR-324-3p − 0.667 0.007 0.183 0.257 − 0.053 0.857 − 0.448 0.004 0.270 0.330 − 0.293 0.066
miR-363-3p − 0.463 0.082 0.075 0.644 0.070 0.811 − 0.582  < 0.001 0.125 0.657 − 0.189 0.244
miR-454-3p − 0.692 0.004 0.085 0.603 − 0.290 0.315 − 0.293 0.070 0.250 0.368 − 0.416 0.008
miR-532-5p − 0.480 0.070 0.283 0.077 − 0.058 0.844 − 0.487 0.002 0.217 0.438 − 0.308 0.053
miR-629-5p − 0.383 0.159 − 0.057 0.729 0.017 0.954 − 0.419 0.008 0.151 0.592 − 0.057 0.728
miR-660-5p − 0.500 0.058 0.102 0.530 0.313 0.276 − 0.538  < 0.001 0.231 0.407 − 0.118 0.467
8
Vol:.(1234567890)
Scientific Reports |         (2021) 11:7517  | https://doi.org/10.1038/s41598-021-87086-1
www.nature.com/scientificreports/
Methods
Study population and design. This was a prospective cross-sectional study. Inclusion criteria were 
patients with clinical features of  DCM1, a LV end-diastolic diameter larger than 56 mm and a LVEF below 50%. 
Exclusion criteria were genetic DCM or any cardiovascular, life-limiting systemic condition or an infectious or 
tumoral condition that could influence the DCM definition or miRNA results. Only patients older than 18 years 
old were enrolled. A total of 159 consecutive subjects were included in the study: (1) 55 idiopathic DCM patients, 
(2) 60 ischemic DCM and (3) 44 healthy controls who had been referred to the Cardiology Department of the 
University Hospital Puerta del Mar, Cádiz, Spain. The study design is shown in Fig. 1. LVEF was classified into 
two categories based on prior studies: ≤ 30%, severely reduced EF  (DCMSEV) and 31–49% moderately reduced EF 
 (DCMMOD)49,50. A transthoracic echocardiography protocol was performed as described  previously13,15. Echo-
cardiographic methods for the measurement of EF were the apical biplane method of disks (modified Simpson’s 
rule) and when this was not possible,  Teicholz51. Detailed anthropometric, clinical and pharmacological infor-
mation was obtained from each subject including family history, symptoms of HF, an electrocardiogram, a 24-h 
Holter electrocardiogram and, when appropriate, cardiac magnetic resonance. Our institution’s ethics commit-
tee (Comité de Ética de la Investigación de Cádiz) approved the study protocol. The study was performed in full 
compliance with the Helsinki II Declaration. All participants provided written informed consent.
Blood collection. Ten millilitres of peripheral blood were collected in K2-ethylenediaminetetraacetic acid 
tubes (BD) after 10 h overnight fasting and were immediately centrifuged (1500 xg, 15 min, 4 °C). The blood was 
processed within 4 h after isolation. The upper layer containing plasma was divided into aliquots and stored at 
-80ºC until further analysis.
RNA isolation. Total RNA was isolated using a miRNeasy Serum/Plasma Kit (Qiagen), according to the 
manufacturer’s instructions. A total of 200 µL of plasma aliquots were used to obtain enough final volume. 
To normalize extracellular miRNAs, a mix of synthetic Caenorhabditis Elegans miR-39-3p (cel-miR-39-3p) 
(1.6 ×  108 copies/µL) (Qiagen) and UniSp6 (Qiagen) was added to each sample. RNA was stored at -80 °C.
MicroRNA real‑time reverse transcriptase‑polymerase chain reaction. RNA was reverse tran-
scribed using the miRCURY LNA RT Kit (Qiagen) as previously  described15. The reverse transcription reaction 
was performed under the following conditions: 60 min at 42 ºC, heat-inactivated for 5 min at 95 ºC and imme-
Figure 2.  Boxplots of miRNA expression levels, normalized to cel-miR-39-3p, in healthy subjects, idiopathic 
 DCMMOD and  DCMSEV. The analysis was carried out using qPCR. Data are presented in  log2. Data represent the 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations:  DCMMOD, dilated cardiomyopathy with ejection 
fraction ≥ 31–49%;  DCMSEV, dilated cardiomyopathy with ejection fraction ≤ 30%.
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Figure 3.  Correlation between the LVEF parameter and individual microRNAs for LVEF categorization 
in idiopathic DCM. (A-N) LVEF was independently negatively related with let-7a-5p (A), let 7 g-5p (B), 
miR-19b-3p (C), miR-25-3p (D), miR-29a-3p (E), miR-30b-5p (F), miR-30e-3p (G), miR-142-3p (H), miR-
145-5p (I), miR-150-5p (J), miR-199a-3p (K), miR-210-3p (L), , miR-324-3p (M) and miR-660-5p (N) 
levels. Abbreviations:  DCMMOD, dilated cardiomyopathy with ejection fraction ≥ 31–49%;  DCMSEV, dilated 
cardiomyopathy with ejection fraction ≤ 30%.
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Table 5.  Comparisons of single microRNAs as predictors of idiopathic  DCMSEV from  DCMMOD and their 
diagnostic value. Abbreviations: AUC, area under the curve; CI, confidence interval;  DCMSEV, dilated 
cardiomyopathy with ejection fraction ≤ 30%; miRNA, microRNA; ROC, receiver operating characteristic.

















































































































Table 6.  Multivariate logistic regression analysis for identification of independent predictors of idiopathic 
 DCMSEV patients. AIC value: 35.406. The model included LBBB (%), LVESD (mm), SBP (mm Hg), smoking 
habit and the levels of miR-130b-3p,miR-150-5p and miR-210-3p. Abbreviations: AIC, Aikaike Information 
Criterion; CI, confidence interval; LBBB, left bundle branch block; LVESD, left ventricular end-systolic 
diameter; OR, odds ratio; SBP, systolic blood pressure.
Variable OR 95% CI p
LBBB (%) 18.13 1.28–257.21 0.014
LVESD (mm) 1.24 1.01–1.53 0.01
SBP (mm Hg) 0.97 0.91–1.03 0.329
Smoking habit 30.1 1.44–630.02 0.007
miR-130b-3p 0 0.1–1.57 0.01
miR-150-5p 36.06 1.64–794.78 0.006
miR-210-3p 687.53 0.9–527,268.21  < 0.001
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diately cooled to 4 ºC. Then cDNA was stored at − 20 ºC. Quantitative real-time PCR (qPCR) was performed 
according to the protocol of miRCURY LNA SYBR Green PCR Kit (Qiagen). CFX Connect PCR System (Bio-
Rad) was used to perform the qPCR, at 95 °C for 2 min, followed by 40 cycles of 95 °C for 10 s, and 56 °C for 
60 s, followed by melting curve analysis. qPCR amplification curves were evaluated with CFX Manager™ software 
(BioRad). The specificity of the amplification was corroborated by melting curve analysis.
The miRCURY LNA miRNA Serum/Plasma Focus PCR Panel (Qiagen) was used for the screening study. 
This panel contains 179 miRNA primer sets expressed in human serum/plasma. Then, custom 96-wells Pick-
&-Mix microRNA PCR plates (Qiagen) were used to validate each miRNA candidate. To account for the vari-
ability between the plates, the interplate calibrator UniSp3 was analysed. Cqs above 35 cycles were censored 
at the minimum level observed for each miRNA. cel-miR-39-3p levels were stable across all samples. Relative 
quantification was performed using the 2 − ΔCq method, where ΔCq = CqmiRNA − Cqcel-miR-39-3p miRNA 
levels were log-transformed before being used in the statistical analyses. We have previously used this approach 
in the field of circulating non-coding  RNAs13,15.
miRNA‑gene network analysis. The miRNAs obtained were tested using the miRDB database (http:// 
mirdb. org/) to predict the targeted  genes52. A database analysis to identify the biological function was per-
formed using GO enrichment analysis (http:// geneo ntolo gy. org/)53 and the KEGG (https:// www. kegg. jp/ kegg/) 
 software54. R software (www.r- proje ct. org) was assessed to build up miRNA-mRNA55. The STRING database 
(http:// www. string- db. org/) was used to analyse the PPI  networks56.
Statistical analysis. Continuous variables are shown as mean ± standard deviation. Categorical variables 
are expressed as frequency and percentage of patients (%). Intergroup comparisons of miRNAs levels were per-
formed using non-parametric Mann–Whitney and Kruskal–Wallis rank tests for continuous variables. The Pear-
son correlation coefficient was used for correlations between echocardiographic and clinical parameters vs.  log2 
miRNAs. An analysis of differences between groups was performed using analysis of variance. Receiver operat-
ing characteristic (ROC) curves that characterize the diagnostic performance of candidate miRNAs and logistic 
regression models were plotted to determine the area under the curve (AUC) and the specificity and sensitivity 
of the optimal cut-offs. ROC curves were generated by plotting sensitivity against 100-specificity. Data were 
presented as the AUC and 95% confidence intervals. The relationships between miRNAs and LVEF status were 
assessed using logistic regression. Multiple logistic regression modelling was applied to perform the miRNA 
panel. The regression coefficients of each miRNA that was significantly associated with the outcome were applied 
to estimate the miRNA panel value. The Wilcoxon test and iterating combinations between our miRNA candi-
dates, as well as echocardiographic and clinical covariates, were used to construct several models. The changes in 
p-values of their variables were evaluated by the Wald test and a likelihood ratio. The statistical software package 
R (www.r- proje ct. org) was used for all  analyses55.
Figure 4.  ROC analysis for the multivariate logistic regression model predicting idiopathic  DCMSEV patients. 
The mean AUC for the averaged ROC curves are presented. The data are presented as the AUC and 95% CI 
and corresponding sensitivity for a range of specificities. The AUC is 0.96 (95% CI: 0.884–1.00; p < 0.001). 
Abbreviations: AUC, area under the curve; CI, confidence interval;  DCMSEV, dilated cardiomyopathy with 
ejection fraction ≤ 30%; ROC, receiver operating characteristic.
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Figure 5.  The miRNA-gene network for miRNAs associated with genes related to idiopathic  DCMSEV. (A) 
Venn diagram showing overlap of gene targets of miR-130b-3p, miR-150-5p and miR-210-3p. (B) GO and 
KEGG analysis of miR-130b-3p, miR-150-5p and miR-210-3p target genes; the x-axis indicates KEGG pathway 
categories and the y-axis indicates the target numbers of genes. (C) miRNA-gene network for miR-210-3p. 
The network was built using 83 targeted genes and predicted interactions from the miRDB database. (D) PPI 
analysis performed using the STRING database for the target genes of miR-210-3p. The disconnected nodules 
are hidden. Bold lines indicate stronger association. Abbreviations:  DCMSEV, dilated cardiomyopathy with 
ejection fraction ≤ 30%.
13
Vol.:(0123456789)
Scientific Reports |         (2021) 11:7517  | https://doi.org/10.1038/s41598-021-87086-1
www.nature.com/scientificreports/
Data availability
The authors confirm that the data supporting the findings of this study are available within the article and its 
supplementary materials.
Received: 11 June 2020; Accepted: 23 March 2021
References
 1. Elliott, P. et al. Classification of the cardiomyopathies: A position statement from the european society of cardiology working group 
on myocardial and pericardial diseases. Eur. Heart. J. 29(2), 270–276. https:// doi. org/ 10. 1093/ eurhe artj/ ehm342 (2008).
 2. Merlo, M. et al. Evolving concepts in dilated cardiomyopathy. Eur. J. Heart Fail. https:// doi. org/ 10. 1002/ ejhf. 1103 (2017).
 3. Schultheiss, H. P. et al. Dilated cardiomyopathy. Nat. Rev. Dis. Prim. https:// doi. org/ 10. 1038/ s41572- 019- 0084-1 (2019).
 4. Branca, L., Sbolli, M., Metra, M. & Fudim, M. Heart failure with mid-range ejection fraction: pro and cons of the new classification 
of Heart Failure by European Society of Cardiology guidelines. ESC Hear Fail. 7(2), 381–399. https:// doi. org/ 10. 1002/ ehf2. 12586 
(2020).
 5. Witt, C. M. et al. Outcomes with left bundle branch block and mildly to moderately reduced left ventricular function. JACC Hear 
Fail. 4(11), 897–903. https:// doi. org/ 10. 1016/j. jchf. 2016. 07. 002 (2016).
 6. Gentile, P. et al. Dilated cardiomyopathy with mid-range ejection fraction at diagnosis: characterization and natural history. J. Am. 
Heart Assoc. 8(17), e010705. https:// doi. org/ 10. 1161/ JAHA. 118. 010705 (2019).
 7. Angaran, P. et al. Association of left ventricular ejection fraction with mortality and hospitalizations. J. Am. Soc. Echocardiogr. 
S0894–7317(20), 30009–30012. https:// doi. org/ 10. 1016/j. echo. 2019. 12. 016 (2020).
 8. Rusnak, J. et al. Impact of left ventricular ejection fraction on recurrent ventricular tachyarrhythmias in recipients of implantable 
cardioverter defibrillators. Cardiology https:// doi. org/ 10. 1159/ 00050 4876 (2020).
 9. Calderon-Dominguez, M. et al. Emerging role of microRNAs in dilated cardiomyopathy: evidence regarding etiology. Transl. Res. 
215, 86–101. https:// doi. org/ 10. 1016/j. trsl. 2019. 08. 007 (2019).
 10. Stepien, E. et al. The circulating non-coding RNA landscape for biomarker research: Lessons and prospects from cardiovascular 
diseases review-article. Acta Pharmacol Sin. 39(7), 1085–1099. https:// doi. org/ 10. 1038/ aps. 2018. 35 (2018).
 11. Colpaert, R. M. W. & Calore, M. MicroRNAs in cardiac diseases. Cells 8(7), 737. https:// doi. org/ 10. 3390/ cells 80707 37 (2019).
 12. Lu, D. & Thum, T. RNA-based diagnostic and therapeutic strategies for cardiovascular disease. Nat. Rev. Cardiol. 16(11), 661–674. 
https:// doi. org/ 10. 1038/ s41569- 019- 0218-x (2019).
 13. Toro, R. et al. Plasma microRNAs as biomarkers for Lamin A/C-related dilated cardiomyopathy. J. Mol. Med. 96(8), 845–856 (2018).
 14. Zaragoza, C. et al. Differential expression of circulating miRNAs as a novel tool to assess BAG3-associated familial dilated cardio-
myopathy. Biosci Rep. 39(3), BSR20180934. https:// doi. org/ 10. 1042/ BSR20 180934 (2019).
 15. Belmonte, T. et al. Peripheral microRNA panels to guide the diagnosis of familial cardiomyopathy. Transl Res. 218, 1–15. https:// 
doi. org/ 10. 1016/j. trsl. 2020. 01. 003 (2020).
 16. Al-Khatib, S. M. et al. Preventing tomorrow’s sudden cardiac death today. Dissemination of effective therapies for sudden cardiac 
death prevention. Am. Heart J. 156(4), 613–622. https:// doi. org/ 10. 1016/j. ahj. 2008. 05. 027 (2008).
 17. Wu, T. et al. Circulating exosomal miR-92b-5p is a promising diagnostic biomarker of heart failure with reduced ejection fraction 
patients hospitalized for acute heart failure. J. Thorac Dis. 10(11), 6211–6220. https:// doi. org/ 10. 21037/ jtd. 2018. 10. 52 (2018).
 18. Watson, C. J. et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur. J. Heart Fail. 
17(4), 405–415. https:// doi. org/ 10. 1002/ ejhf. 244 (2015).
 19. Chen, F., Yang, J., Li, Y. & Wang, H. Circulating microRNAs as novel biomarkers for heart failure. Hell J. Cardiol. 59(4), 209–214. 
https:// doi. org/ 10. 1016/j. hjc. 2017. 10. 002 (2018).
 20. Wong, L. L. et al. Combining circulating MicroRNA and NT-proBNP to detect and categorize heart failure subtypes. J. Am. Coll 
Cardiol. 73(11), 1300–1313. https:// doi. org/ 10. 1016/j. jacc. 2018. 11. 060 (2019).
 21. Domínguez, F. et al. Dilated cardiomyopathy due to BLC2-associated athanogene 3 (BAG3) mutations. J. Am. Coll Cardiol. 72(20), 
2471–2481. https:// doi. org/ 10. 1016/j. jacc. 2018. 08. 2181 (2018).
 22. Dziewięcka, E. et al. Relations between circulating and myocardial fibrosis-linked microRNAs with left ventricular reverse remod-
eling in dilated cardiomyopathy. Adv. Clin. Exp. Med. 29(3), 285–293. https:// doi. org/ 10. 17219/ acem/ 115088 (2020).
 23. Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 37(27), 
2129–2200m. https:// doi. org/ 10. 1093/ eurhe artj/ ehw128 (2016).
 24. Merlo, M. et al. Arrhythmic risk stratification in patients with dilated cardiomyopathy and intermediate left ventricular dysfunc-
tion. J. Cardiovasc. Med. 20(5), 343–350. https:// doi. org/ 10. 2459/ JCM. 00000 00000 000792 (2019).
 25. Marques, F. Z., Vizi, D., Khammy, O., Mariani, J. A. & Kaye, D. M. The transcardiac gradient of cardio-microRNAs in the failing 
heart. Eur. J. Heart Fail. 18(8), 1000–1008. https:// doi. org/ 10. 1002/ ejhf. 517 (2016).
 26. Priest, J. R. et al. De Novo and rare variants at multiple loci support the oligogenic origins of atrioventricular septal heart defects. 
PLoS Genet. 12(4), 1–25. https:// doi. org/ 10. 1371/ journ al. pgen. 10059 63 (2016).
 27. Guan, R. et al. Knockdown of ZNF403 inhibits cell proliferation and induces G2/M arrest by modulating cell-cycle mediators. 
Mol. Cell Biochem. 365(1–2), 211–222. https:// doi. org/ 10. 1007/ s11010- 012- 1262-6 (2012).
 28. King, J. C. et al. E2F3 plays an essential role in cardiac development and function. Cell Cycle 7(23), 3775–3780. https:// doi. org/ 10. 
4161/ cc.7. 23. 7240 (2008).
 29. Li, X. et al. MicroRNA-150 aggravates H2O2-induced cardiac myocyte injury by down-regulating c-myb gene. Acta Biochim 
Biophys Sin (Shanghai). 45(9), 734–741. https:// doi. org/ 10. 1093/ abbs/ gmt067 (2013).
 30. Mutharasan, R. K., Nagpal, V., Ichikawa, Y. & Ardehali, H. microRNA-210 is upregulated in hypoxic cardiomyocytes through 
Akt- and p53-dependent pathways and exerts cytoprotective effects. Am. J. Physiol. Hear Circ. Physiol. https:// doi. org/ 10. 1152/ 
ajphe art. 01080. 2010 (2011).
 31. Arif, M. et al. MicroRNA-210-mediated proliferation, survival, and angiogenesis promote cardiac repair post myocardial infarction 
in rodents. J. Mol. Med. 95(12), 1369–1385. https:// doi. org/ 10. 1007/ s00109- 017- 1591-8 (2017).
 32. Bian, W. S. et al. MIR-210 protects cardiomyocytes from OGD/R injury by inhibiting E2F3. Eur. Rev. Med. Pharmacol. Sci. 22(3), 
743–749. https:// doi. org/ 10. 26355/ eurrev_ 201802_ 14305 (2018).
 33. Qiao, X. R., Wang, L., Liu, M., Tian, Y. & Chen, T. MiR-210-3p attenuates lipid accumulation and inflammation in atherosclerosis 
by repressing IGF2. Biosci. Biotechnol. Biochem. 84(2), 321–329. https:// doi. org/ 10. 1080/ 09168 451. 2019. 16853 70 (2020).
 34. Sun, W. et al. MicroRNA-210 Modulates the Cellular Energy Metabolism Shift during H2O2 -Induced Oxidative Stress by Repress-
ing ISCU in H9c2 Cardiomyocytes. Cell Physiol. Biochem. 43(1), 383–394. https:// doi. org/ 10. 1159/ 00048 0417 (2017).
 35. Marin-Garcia, J., Goldenthal, M. J., Pierpont, M. E. M. & Ananthakrishnan, R. Impaired mitochondrial function in idiopathic 
dilated cardiomyopathy: biochemical and molecular analysis. J. Card Fail. 1(4), 285–291. https:// doi. org/ 10. 1016/ 1071- 9164(95) 
90003-9 (1995).
 36. Jarreta, D. et al. Mitochondrial function in heart muscle from patients with idiopathic dilated cardiomyopathy. Cardiovasc Res. 
45(4), 860–865. https:// doi. org/ 10. 1016/ S0008- 6363(99) 00388-0 (2000).
14
Vol:.(1234567890)
Scientific Reports |         (2021) 11:7517  | https://doi.org/10.1038/s41598-021-87086-1
www.nature.com/scientificreports/
 37. Devaux, Y. et al. MicroRNA-150: A novel marker of left ventricular remodeling after acute myocardial infarction. Circ. Cardiovasc. 
Genet. 6(3), 290–298. https:// doi. org/ 10. 1161/ CIRCG ENETI CS. 113. 000077 (2013).
 38. Lin, X., Zhang, S. & Huo, Z. Serum circulating miR-150 is a predictor of post-acute myocardial infarction heart failure. Int Heart 
J. 60(2), 280–286. https:// doi. org/ 10. 1536/ ihj. 18- 306 (2019).
 39. Tang, Y. Y. et al. MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death. Cardiovasc Res. 106(3), 
387–397. https:// doi. org/ 10. 1093/ cvr/ cvv121 (2015).
 40. Scrutinio, D. et al. Circulating microRNA-150-5p as a novel biomarker for advanced heart failure: a genome-wide prospective 
study. J. Hear Lung Transplant. 36(6), 616–624. https:// doi. org/ 10. 1016/j. healun. 2017. 02. 008 (2017).
 41. Feridooni, T., Hotchkiss, A., Remley-Carr, S., Saga, Y. & Pasumarthi, K. B. S. Cardiomyocyte specific ablation of p53 is not sufficient 
to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes. PLoS ONE 6, 7. https:// doi. org/ 10. 1371/ journ 
al. pone. 00228 01 (2011).
 42. Chu, X. et al. miR-130 aggravates acute myocardial infarction-induced myocardial injury by targeting PPAR-γ. J. Cell Biochem. 
119(9), 7235–7244. https:// doi. org/ 10. 1002/ jcb. 26903 (2018).
 43. Lund, L. H. et al. Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and pre-
served ejection fraction. Eur. Heart J. 34(7), 529–539. https:// doi. org/ 10. 1093/ eurhe artj/ ehs305 (2013).
 44. Daubert, C. et al. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly 
symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses 
Remodeling in Systolic Le. J. Am. Coll Cardiol. 54(20), 1837–1846. https:// doi. org/ 10. 1016/j. jacc. 2009. 08. 011 (2009).
 45. Al-Khatib, S. M. et al. 2017 AHA/ACC/HRS Guideline for management of patients with ventricular arrhythmias and the preven-
tion of sudden cardiac death. Circulation 138(13), e272–e391. https:// doi. org/ 10. 1161/ CIR. 00000 00000 000549 (2018).
 46. Sanders, G. D., Hlatky, M. A. & Owens, D. K. Cost-effectiveness of implantable cardioverter-defibrillators. N. Engl. J. Med. 353(14), 
1471–1480. https:// doi. org/ 10. 1056/ NEJMs a0519 89 (2005).
 47. Cannatà, A. et al. Sex differences in the long-term prognosis of dilated cardiomyopathy. Can. J. Cardiol. 36(1), 37–44. https:// doi. 
org/ 10. 1016/j. cjca. 2019. 05. 031 (2020).
 48. Yogasundaram, H., Qi, A., Nguyen, Q. & Oudit, G. Y. Battle of the sexes: differential prognosis by sex in dilated cardiomyopathy. 
Can. J. Cardiol. 36(1), 7–10. https:// doi. org/ 10. 1016/j. cjca. 2019. 06. 031 (2020).
 49. Bänsch, D. et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial 
(CAT). Circulation 105(12), 1453–1458. https:// doi. org/ 10. 1161/ 01. CIR. 00000 12350. 99718. AD (2002).
 50. Dewan, P. et al. Differential impact of heart failure with reduced ejection fraction on men and women. J. Am. Coll Cardiol. 73(1), 
29–40. https:// doi. org/ 10. 1016/j. jacc. 2018. 09. 081 (2019).
 51. Galderisi, M. et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantifi-
cation, diastolic function, and heart valve disease recommendations: An expert consensus document of the European Association 
of Cardiovascular Imag. Eur. Heart J. Cardiovasc Imaging. 18(12), 1301–1310. https:// doi. org/ 10. 1093/ ehjci/ jex244 (2017).
 52. Chen, Y. & Wang, X. miRDB: an online database for prediction of functional microRNA targets. Nucleic Acids Res. 48(D1), D127–
D131. https:// doi. org/ 10. 1093/ nar/ gkz757 (2020).
 53. Mi, H., Muruganujan, A., Ebert, D., Huang, X. & Thomas, P. D. PANTHER version 14: More genomes, a new PANTHER GO-slim 
and improvements in enrichment analysis tools. Nucleic Acids Res. 47(D1), D419–D426. https:// doi. org/ 10. 1093/ nar/ gky10 38 
(2019).
 54. Kanehisa, M. & Goto, S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27–30. https:// doi. org/ 10. 
1093/ nar/ 28.1. 27 (2000).
 55. Team RC. R: A Language and Environment for Statistical Computing. https:// www.r- proje ct. org
 56. Szklarczyk, D. et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery 
in genome-wide experimental datasets. Nucleic Acids Res. 47(D1), D607–D613. https:// doi. org/ 10. 1093/ nar/ gky11 31 (2019).
Acknowledgements
This study was supported by the Fundación Pública Andaluza Progreso y Salud para la Financiación, co-
financed by the European Regional Development Fund (ERDF) (PI-0048-2017), Plan Propio de INIBICA (PI-
INBICA2019-13), Fundación Pública Andaluza Progreso y Salud (PI 0136-2018). The study was also supported 
by a grant from the Spanish Society of Cardiology (SEC) for Basic Research (0011-2019). We would like to thank 
Galan Pacheco for statistical support.
Author contributions
M.C-D., T.B., A.M.and R.T. conceived the experiments, M.Q-F., M.R., O.C., A.M. and R.T. recruited the subjects, 
M.C-D., T.B., J.C-D.and R.T. conducted the experiments, M.C-D., T.B., J.C-D.and R.T. analyzed the results. M.C-
D., T.B., A.M. and R.T. wrote the manuscript. All authors reviewed the manuscript.
Competing interests 
The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 
10. 1038/ s41598- 021- 87086-1.
Correspondence and requests for materials should be addressed to M.C.-D. or R.T.
Reprints and permissions information is available at www.nature.com/reprints.




Scientific Reports |         (2021) 11:7517  | https://doi.org/10.1038/s41598-021-87086-1
www.nature.com/scientificreports/
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
